# Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

> **NCT02573896** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 13 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Dinutuximab
- **BIOLOGICAL:** NK Cells
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02573896
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-14
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573896, "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02573896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*